uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 09 04 2020
accepted: 06 11 2020
revised: 02 11 2020
pubmed: 26 11 2020
medline: 10 4 2021
entrez: 25 11 2020
Statut: ppublish

Résumé

Exosomes (Exos) have been reported to promote pre-metastatic niche formation, proliferation, angiogenesis and metastasis. We have investigated the role of uPAR in melanoma cell lines-derived Exos and their pro-angiogenic effects on human microvascular endothelial cells (HMVECs) and endothelial colony-forming cells (ECFCs). Melanoma Exos were isolated from conditioned media of A375 and M6 cells by differential centrifugation and filtration. Tunable Resistive Pulse Sensing (TRPS) and Nanoparticle tracking analysis were performed to analyze dimension and concentration of Exos. The CRISPR-Cas 9 technology was exploited to obtain a robust uPAR knockout. uPAR is expressed in melanoma Exos that are internalized by HMVECs and ECFCs, enhancing VE-Cadherin, EGFR and uPAR expression in endothelial cells that undergo a complete angiogenic program, including proliferation, migration and tube formation. uPAR loss reduced the pro-angiogenic effects of melanoma Exos in vitro and in vivo by inhibition of VE-Cadherin, EGFR and uPAR expression and of ERK1,2 signaling in endothelial cells. A similar effect was obtained with a peptide that inhibits uPAR-EGFR interaction and with the EGFR inhibitor Gefitinib, which also inhibited melanoma Exos-dependent EGFR phosphorylation. This study suggests that uPAR is required for the pro-angiogenic activity of melanoma Exos. We propose the identification of uPAR-expressing Exos as a potentially useful biomarker for assessing pro-angiogenic propensity and eventually monitoring the response to treatment in metastatic melanoma patients.

Identifiants

pubmed: 33237352
doi: 10.1007/s00018-020-03707-4
pii: 10.1007/s00018-020-03707-4
pmc: PMC8004497
doi:

Substances chimiques

Antigens, CD 0
Cadherins 0
RNA, Small Interfering 0
Receptors, Urokinase Plasminogen Activator 0
cadherin 5 0
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24
Gefitinib S65743JHBS

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3057-3072

Références

Dermatol Clin. 2019 Apr;37(2):159-168
pubmed: 30850038
Anticancer Res. 2016 Mar;36(3):957-65
pubmed: 26976984
Int J Cancer. 2005 Dec 20;117(6):883-8
pubmed: 16152621
Curr Opin Cell Biol. 2009 Aug;21(4):575-81
pubmed: 19442504
Clin Cancer Res. 2002 May;8(5):1132-41
pubmed: 12006529
Oncotarget. 2018 Apr 17;9(29):20826-20837
pubmed: 29755693
Hematol Oncol Clin North Am. 2004 Oct;18(5):1007-21, viii
pubmed: 15474332
Nat Med. 2016 Dec 6;22(12):1502
pubmed: 27923027
J Biol Chem. 2001 Feb 16;276(7):4756-65
pubmed: 11085980
Int J Cancer. 2017 Sep 15;141(6):1190-1200
pubmed: 28577299
Expert Rev Mol Diagn. 2010 Nov;10(8):1051-67
pubmed: 21080821
Cancer. 2015 Jan 1;121(1):51-9
pubmed: 25155861
Nat Rev Cancer. 2009 Jan;9(1):40-55
pubmed: 19078974
Int J Mol Sci. 2020 Apr 22;21(8):
pubmed: 32331267
Int J Mol Sci. 2019 Dec 20;21(1):
pubmed: 31861757
EBioMedicine. 2019 Jan;39:194-206
pubmed: 30611716
J Mol Med (Berl). 2015 Jul;93(7):783-94
pubmed: 25694039
Clin Appl Thromb Hemost. 2003 Jul;9(3):241-6
pubmed: 14507113
Oncotarget. 2016 May 24;7(21):30659-77
pubmed: 27120791
Clin Lab. 2017 Nov 1;63(11):1949-1953
pubmed: 29226653
Blood. 2011 Sep 29;118(13):3743-55
pubmed: 21803847
Arthritis Rheum. 2006 Dec;54(12):3926-38
pubmed: 17133606
Semin Cancer Biol. 2019 Dec;59:251-265
pubmed: 31386906
Blood. 2011 Apr 14;117(15):4154-61
pubmed: 21304107
Cancer Res. 2015 Apr 1;75(7):1169-76
pubmed: 25788696
Nat Cell Biol. 2018 Mar;20(3):332-343
pubmed: 29459780
Cancer J. 2015 Jul-Aug;21(4):284-93
pubmed: 26222080
PLoS One. 2015 Aug 28;10(8):e0133592
pubmed: 26317203
Nat Commun. 2011;2:229
pubmed: 21407195
Nat Cell Biol. 2014 Apr;16(4):309-21
pubmed: 24658686
Cold Spring Harb Perspect Biol. 2011 Aug 01;3(8):a004721
pubmed: 21576253
J Extracell Vesicles. 2016 Mar 24;5:29289
pubmed: 27018366
Cancer Sci. 2004 Jul;95(7):614-8
pubmed: 15245600
Int J Oncol. 2018 Apr;52(4):1071-1080
pubmed: 29532857
Curr Cancer Drug Targets. 2009 Feb;9(1):32-71
pubmed: 19200050
Int J Cancer. 2015 Sep 15;137(6):1406-16
pubmed: 25754273
Mol Cancer. 2014 Apr 26;13:88
pubmed: 24766647
Expert Rev Proteomics. 2017 Jan;14(1):69-95
pubmed: 27838931
Curr Top Dev Biol. 2015;112:325-52
pubmed: 25733145
Biochim Biophys Acta. 2014 Jan;1841(1):108-20
pubmed: 24140720
Cells. 2020 Jan 28;9(2):
pubmed: 32012858
Int Rev Cell Mol Biol. 2010;282:135-63
pubmed: 20630468
J Cell Mol Med. 2015 Jan;19(1):113-23
pubmed: 25313007
Front Immunol. 2014 Sep 16;5:442
pubmed: 25278937
Biochem Biophys Res Commun. 2019 Jan 8;508(2):405-409
pubmed: 30503342
Cancer Res. 2006 Feb 15;66(4):2173-80
pubmed: 16489018
PLoS One. 2016 Mar 23;11(3):e0152213
pubmed: 27006994
Sci Rep. 2018 Aug 27;8(1):12905
pubmed: 30150674
Arthritis Rheum. 2004 Oct;50(10):3275-85
pubmed: 15476218
Cancers (Basel). 2016 Dec 09;8(12):
pubmed: 27941674
Blood. 2011 Apr 14;117(15):3941-3
pubmed: 21493804
Blood. 2010 Jun 17;115(24):5111-20
pubmed: 20228268
Int J Mol Sci. 2016 Feb 06;17(2):175
pubmed: 26861306

Auteurs

Alessio Biagioni (A)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Anna Laurenzana (A)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Beatrice Menicacci (B)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Silvia Peppicelli (S)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Elena Andreucci (E)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Francesca Bianchini (F)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Daniele Guasti (D)

Department of Experimental and Clinical Medicine, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy.

Paolo Paoli (P)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Simona Serratì (S)

Nanotecnology Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", Viale Orazio Flacco, 65, 70124, Bari, Italy.

Alessandra Mocali (A)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Lido Calorini (L)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Mario Del Rosso (M)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Gabriella Fibbi (G)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy.

Anastasia Chillà (A)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy. anastasia.chilla@unifi.it.

Francesca Margheri (F)

Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Viale G.B. Morgagni, 50, 50134, Florence, Italy. francesca.margheri@unifi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH